Carvedilol update III: Rationale for use in congestive heart failure

G. Z. Feuerstein, George Poste, R. R. Ruffolo

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.

Original languageEnglish (US)
Pages (from-to)307-326
Number of pages20
JournalDrugs of Today
Volume31
Issue number5
StatePublished - 1995
Externally publishedYes

Fingerprint

Heart Failure
Placebos
Cardiovascular Agents
Mortality
Digitalis
Controlled Clinical Trials
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Clinical Trials
carvedilol
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Feuerstein, G. Z., Poste, G., & Ruffolo, R. R. (1995). Carvedilol update III: Rationale for use in congestive heart failure. Drugs of Today, 31(5), 307-326.

Carvedilol update III : Rationale for use in congestive heart failure. / Feuerstein, G. Z.; Poste, George; Ruffolo, R. R.

In: Drugs of Today, Vol. 31, No. 5, 1995, p. 307-326.

Research output: Contribution to journalArticle

Feuerstein, GZ, Poste, G & Ruffolo, RR 1995, 'Carvedilol update III: Rationale for use in congestive heart failure', Drugs of Today, vol. 31, no. 5, pp. 307-326.
Feuerstein, G. Z. ; Poste, George ; Ruffolo, R. R. / Carvedilol update III : Rationale for use in congestive heart failure. In: Drugs of Today. 1995 ; Vol. 31, No. 5. pp. 307-326.
@article{5aac6300d1494469af7ce1aaca4ab6af,
title = "Carvedilol update III: Rationale for use in congestive heart failure",
abstract = "In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.",
author = "Feuerstein, {G. Z.} and George Poste and Ruffolo, {R. R.}",
year = "1995",
language = "English (US)",
volume = "31",
pages = "307--326",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Carvedilol update III

T2 - Rationale for use in congestive heart failure

AU - Feuerstein, G. Z.

AU - Poste, George

AU - Ruffolo, R. R.

PY - 1995

Y1 - 1995

N2 - In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.

AB - In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.

UR - http://www.scopus.com/inward/record.url?scp=0029145195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029145195&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029145195

VL - 31

SP - 307

EP - 326

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -